Mechanism Study on Synergistic Regulation of Inflammatory-Metabolic Network in Type 2 Diabetes Mellitus by Multi-Components of Chinese Herbal Compound Formula
Main Article Content
Abstract
The progression of type 2 diabetes mellitus is closely interconnected with chronic low-grade inflammation and glycolipid metabolic disorders through complex network interactions. Intervention targeting a single molecular node fails to block the cascade amplification effects of such networks. Chinese herbal compound formulas possess unique advantages in regulating complex pathological networks owing to their integrative characteristics of multiple components and multi-target actions. This paper analyzes the mechanisms by which multiple components of Chinese herbal compound formulas synergistically modulate inflammatory-metabolic networks. An argumentative framework is constructed from three dimensions: the pathological coupling basis, target mapping of compound formulas, and synergistic pathway mechanisms. Combined with animal experiments as well as transcriptomic and metabolomic data, this study identifies the interaction nodes of the AMPK and AKT/mTOR pathways within inflammatory-metabolic networks, and clarifies the bidirectional regulatory effects of multi-component synergistic intervention on insulin resistance and chronic inflammation. The findings provide a theoretical foundation for the clinical application of Chinese herbal compound formulas in the treatment of type 2 diabetes mellitus.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
J. J. Yoon, Y. H. Kim, L. A. Tai, et al., “Ameliorative effects of Wiryeongtang (herbal medicine) on cardiorenal complications via modulation of inflammatory and fibrotic responses in diabetic mice,” Integr. Med. Res., vol. 15, no. 3PA, Art. no. 101322, 2026, doi: 10.1016/J.IMR.2026.101322.
Y. Su, S. Luo, W. Li, et al., “Chinese Herbal Medicines for Diabetic Cardio-Cerebrovascular Diseases: Key Bioactive Metabolites and Action Mechanisms,” J. Nutr. Metab., vol. 2026, no. 1, Art. no. 5563248, 2026, doi: 10.1155/JNME/5563248.
L. Huang, Q. Chen, X. Liu, et al., “Berberine inhibits ISG15 and pyroptosis to attenuate diabetic kidney disease inflammation and fibrosis,” Apoptosis, vol. 31, no. 2, p. 64, 2026, doi: 10.1007/S1 0495-026-02282-6.
Z. Y. Li, F. H. Zhou, X. M. Sun, et al., “Lipid-Lowering and Spot-Clearing Formula Regulates Inflammation-Metabolism Network via Multi-Component Synergy for Type 2 Diabetes Complicated with Hyperlipidemia: Network Pharmacology and Clinical Verification,” J. South. Med. Univ., vol. 46, no. 1, pp. 83–93, 2026.
J. Liu, S. Bai, C. Wu, et al., “Multi level effects of Sanghuang Tongxie Formula on type 2 diabetes rats: a comprehensive analysis from intestinal bacteria to metabolome and transcriptome,” Front. Endocrinol., vol. 16, Art. no. 1562105, 2025, doi: 10.3389/FENDO. 2025.1562105.
J. Luo, Y. Min, L. Zhou, et al., “Jiangtang Tiaozhi Formula Relieves HFD-Induced Obesity Related Type 2 Diabetes by Inhibiting the cGAS-STING Pathway,” J. Cell. Mol. Med., vol. 29, no. 22, Art. no. e70882, 2025, doi: 10.1111/JCMM.70882.
Y. Jiang, H. Yu, Y. Pan, et al., “Effect and Mechanism of Qi-hua Tongtiao Formula (QHTTF) on Improving Glucose and Lipid Metabolism Disorders in ZDF Rats by Integrating Network Pharmacology, Metabolomics, and Biological Validation,” Pharmaceuticals, vol. 18, no. 9, Art. no. 1347, 2025, doi: 10.3390/PH18091347.
S. L. Dong, X. C. Xue, Q. J. Gao, et al., “Advantages of Chinese Medicines for Diabetic Retinopathy and Mechanisms: Focused on Inflammation and Oxidative Stress,” Chin. J. Integr. Med., vol. 31, no. 11, pp. 1–10, 2025, doi: 10.1007/S11655-025-3938-2.
J. Li, S. Jiang, K. Chen, et al., “The material basis and mechanism of Xiaokening granules in the treatment of type 2 diabetes mellitus by AKT/mTOR/GSK3β,” Fitoterapia, vol. 186, Art. no. 106823, 2025, doi: 10.1016/J.FITOTE.2025.106823.
R. Li, R. Wang, L. Li, et al., “[Shared Therapeutic Targets of Obesity and Type 2 Diabetes Mellitus and the Intervention Mechanisms of Chinese Herbal Components],” Sichuan Univ. Med. Sci., vol. 56, no. 4, pp. 920–930, 2025, doi: 10.12182/20250760104.
Y. Gong, X. Tian, X. Ma, et al., “New insights into the pharmacological mechanisms of Jinqi Jiangtang Tablets in the treatment of type 2 diabetes mellitus: A multi-omics approach combined with experimental validation,” J. Ethnopharmacol., vol. 350, Art. no. 120020, 2025, doi: 10.1016/J.JEP.2025.120020.
F. Y. Liu, Y. Y. Liu, Y. Xiao, et al., “Shenlian Decoction Amelio-rates LPS-Related Inflammation in db/db Mice: Coupling Network Pharmacology With Experimental Verification,” J. Diabetes Res., vol. 2025, Art. no. 3823051, 2025, doi: 10.1155/JDR/3823051.
Y. Wang, P. Gao, Z. Wu, et al., “Exploring the therapeutic potential of Chinese herbs on comorbid type 2 diabetes mellitus and Parkinson’s disease: A mechanistic study,” J. Ethnopharmacol., vol. 338, no. P3, Art. no. 119095, 2024, doi: 10.1016/J.JEP.2024.119095.
J. Yu, Z. Song, L. Wang, et al., “Mechanisms of Cinnamomi Cortex against Diabetes Mellitus Explored by Network Pharmacology combined with Molecular Docking and Experimental Validation,” Endocr. Metab. Immune Disord. Drug Targets, 2024, doi: 10.2174/0118715303300442240820075910.
M. Yongpo, P. Shengwang, S. Yiming, et al., “Exploring the mechanism of Jingshen Xiaoke decoction in treating T2DM mice based on network pharmacology and molecular docking,” Technol. Health Care, vol. 32, no. 1, pp. 163–179, 2023, doi: 10.3233/THC-220630.
L. Leyu, H. Guoxin, C. Tingbo, et al., “Fufang Fanshiliu Decoction Revealed the Antidiabetic Effect through Modulating Inflammatory Response and Gut Microbiota Composition,” Evid.-Based Complement. Altern. Med., vol. 2022, Art. no. 3255401, 2022, doi: 10.1155/2022/3255401.
N. Qixing, C. Haihong, H. Jielun, et al., “Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota,” Crit. Rev. Food Sci. Nutr., vol. 59, no. 6, pp. 848– 863, 2019, doi: 10.1080/10408398.2018.1536646.